Retro Biosciences vs Saama Analytics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Largest-funded pure-play longevity startup raising $1B Series A at $5B valuation; Sam Altman-backed; pursuing cellular reprogramming, autophagy, and plasma factor therapeutics in parallel; first human trial targeting Australia launch.
About
Retro Biosciences is the largest-funded pure-play longevity company in history, raising $1 billion in Series A financing at a $5 billion valuation with Sam Altman (OpenAI CEO) as a primary backer. The company is pursuing cellular reprogramming, autophagy enhancement, and plasma factor therapeutics in parallel — a multi-pronged approach to extending healthy human lifespan by targeting the cellular hallmarks of aging simultaneously.
Saama Analytics is the #1 AI clinical analytics platform for life sciences; received up to $430M Carlyle-led investment in May 2025; serves 50+ biotech companies across 1,500+ studies including top-20 pharma.
About
Saama Analytics is the leading AI-driven clinical analytics and data management platform for the life sciences industry, positioning itself as the "#1 in AI Clinical Analytics" based on customer adoption across major pharmaceutical and biotechnology companies. Founded and headquartered in the United States, Saama's Life Science Analytics Cloud (LSAC) platform accelerates clinical trial execution by automating data processing, quality checking, safety signal detection, and regulatory submission preparation — tasks that traditionally require significant manual effort from biostatisticians, data managers, and clinical programmers.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.